NMR-STUDY OF THE TRANSFORMING GROWTH-FACTOR-ALPHA (TGF-ALPHA)-EPIDERMAL GROWTH-FACTOR RECEPTOR COMPLEX - VISUALIZATION OF HUMAN TGF-ALPHA BINDING DETERMINANTS THROUGH NUCLEAR OVERHAUSER ENHANCEMENT ANALYSIS
C. Mcinnes et al., NMR-STUDY OF THE TRANSFORMING GROWTH-FACTOR-ALPHA (TGF-ALPHA)-EPIDERMAL GROWTH-FACTOR RECEPTOR COMPLEX - VISUALIZATION OF HUMAN TGF-ALPHA BINDING DETERMINANTS THROUGH NUCLEAR OVERHAUSER ENHANCEMENT ANALYSIS, The Journal of biological chemistry, 271(50), 1996, pp. 32204-32211
The study of human transforming growth factor-alpha (TGF-alpha) in com
plex with the epidermal growth factor (EGF) receptor extracellular dom
ain has been undertaken in order to generate information on the intera
ctions of these molecules. Analysis of H-1 NMR transferred nuclear Ove
rhauser enhancement data for titration of the ligand with the receptor
has yielded specific data on the residues of the growth factor involv
ed in contact with the larger protein. Significant increases and decre
ases in nuclear Overhauser enhancement cross-peak intensity occur upon
complexation, and interpretation of these changes indicates that resi
dues of the A- and C-loops of TGF-alpha form the major binding interfa
ce, while the B-loop provides a structural scaffold for this site. The
se results corroborate the conclusions from NMR relaxation studies (Ho
yt, D. W., Harkins, R. N., Debanne, M. T., O'Connor-McCourt, M., and S
ykes, B. D. (1994) Biochemistry 33, 15283-15392), which suggest that t
he C-terminal residues of the polypeptide are immobilized upon recepto
r binding, while the N terminus of the molecule retains considerable f
lexibility, and are consistent with structure-function studies of the
TGF-alpha/EGF system indicating a multidomain binding model. These res
ults give a visualization, for the first time, of native TGF-alpha in
complex with the EGF receptor and generate a picture of the ligand-bin
ding site based upon the intact molecule. This will undoubtedly be of
utility in the structure-based design of TGF-alpha/EGF agonists and/or
antagonists.